ADMA Biologics

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$117,549
$119,839
$107,191
$81,875
Gross Profit
63,333
59,659
57,311
38,915
EBITDA
38,323
42,188
41,681
23,935
EBIT
40,248
39,634
21,821
Net Income
111,896
35,909
32,062
17,806
Net Change In Cash
117,549
119,839
107,191
81,875
Free Cash Flow
24,286
43,281
-4,580
Cash
103,147
86,707
88,244
45,325
Basic Shares
245,900
244,804
242,167
236,414

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$426,454
$258,214
$154,079
$80,942
Gross Profit
219,553
88,941
35,265
1,173
EBITDA
138,983
5,120
-39,722
-53,334
EBIT
-3,212
-46,835
-58,830
Net Income
197,673
-28,239
-85,183
-84,452
Net Change In Cash
426,454
258,214
154,079
80,942
Cost of Revenue
35,432
-4,832
Free Cash Flow
3,819
-73,419
-125,880
Cash
51,352
86,521
51,089
Basic Shares
243,342
223,977
197,874
139,578

Earnings Calls

Quarter EPS
2024-12-31
$0.13
2024-09-30
$0.15
2024-06-30
$0.13
2024-03-31
$0.08